Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial

American Heart Journal

Volumn 157, Issue 4, 2009, Pages 613-619

  Shrank, William H ^a   Choudhry, Niteesh K ^a   Solomon, Daniel H ^a   Snedden, Thomas M ^b   Lee, Thomas H ^c   Glynn, Robert J ^a   Brown, Theresa V ^b   Jolda, Caitlin ^a   Spetman, Michelle ^a   Brookhart, Maurice Alan ^a   Schneeweiss, Sebastian ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b First Health Services Corporation/Pennsylvania Pharmaceutical Assistance Contract for the Elderly   (United States)

^c PARTNERS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG; HYDROCHLOROTHIAZIDE; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; DIURETICS; DRUG COSTS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; HUMANS; HYDROCHLOROTHIAZIDE; HYPERLIPIDEMIAS; HYPERTENSION; PENNSYLVANIA; PHYSICIANS, FAMILY; PRESCRIPTION DRUGS; SIMVASTATIN;

EID: 63249120866     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.12.006     Document Type: Article

References (28)

1. McGlynn E.A., Asch S.M., Adams J., et al. The quality of health care delivered to adults in the United States. N Engl J Med 348 (2003) 2635-2645
2. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
3. Choudhry N.K., Patrick A.R., Antman E.M., et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 117 (2008) 1261-1268
4. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Available at:. http://www.meps.ahrq.gov/mepsweb/data_stats/tables_compendia_hh_interact ive.jsp?_SERVICE=MEPSSocket0&_PROGRAM=MEPSPGM.TC.SAS&File=HCFY20 06&Table=HCFY2006_CNDXP_C&_Debug= Last accessed January 23, 2009.
5. IMS Health. Top line industry data. Available at:. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d 88f611019418c22a/?vgnextoid=936d9df4609e9110VgnVCM10000071812ca2RCRD &cpsextcurrchannel=1 Last accessed January 23, 2009.
6. Doherty R.B. Assessing the new Medicare prescription drug law. Ann Intern Med 141 (2004) 391-395
7. Kohl H., and Shrank W.H. Increasing generic drug use in Medicare Part D: the role of government. J Am Geriatr Soc 55 (2007) 1106-1109
8. Haas J.S., Phillips K.A., Gerstenberger E.P., et al. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 142 (2005) 891-897
9. Fischer M.A., and Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less?. JAMA 291 (2004) 1850-1856
10. Shrank W.H., Hoang T., Ettner S.L., et al. The implications of choice: prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med 166 (2006) 332-337
11. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560
12. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106 (2002) 3143
13. Donohue J.M., Cevasco M., Rosenthal M.B., et al. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 357 (2007) 673-681
14. Fischer M.A., Schneeweiss S., Avorn J., et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 351 (2004) 2187-2194
15. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2004 summary of findings. Available at:. http://www.kff.org/insurance/7148/loader.cfm?url=/commonspot/security/ge tfile.cfm&PageID=46206 Last accessed October 12, 2004
16. Goldman D.P., Joyce G.F., and Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298 (2007) 61-69
17. Schneeweiss S., Patrick A.R., Maclure M., et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115 (2007) 2128-2135
18. Scott A.B., Culley E.J., and O'Donnell J. Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. J Manag Care Pharm 13 (2007) 412-419
19. Adair R.F., and Holmgren L.R. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med 118 (2005) 881-884
20. Brewer D. The effect of drug sampling policies on residents' prescribing. Fam Med 30 (1998) 482-486
21. Boltri J.M., Gordon E.R., and Vogel R.L. Effect of antihypertensive samples on physician prescribing patterns. Fam Med 34 (2002) 729-731
22. Avorn J., and Soumerai S.B. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med 308 (1983) 1457-1463
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
24. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
25. Public Law 100-293. [H.R. 1207]100th Congress, Apr. 22, 1988. Available at: http://www.fda.gov/opacom/laws/pdma.html. Last accessed September 22, 2008.
26. Shrank W.H., Joseph G.J., Choudhry N.K., et al. Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or the population matter most?. Am J Manag Care 12 (2006) 545-551
27. First DataBank. National drug data file (2007), The Hearst Corporation, San Bruno (CA)
28. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of longitudinal data (2000), Oxford University Press, Oxford, UK 27-32